Cargando…

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure

Cenderitide is a novel designer natriuretic peptide (NP) composed of C‐type natriuretic peptide (CNP) fused to the C‐terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to coactivate the two NP receptors, particulate guanylyl cyclase (pGC)‐A and ‐B. The rationale for its de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakami, Rika, Lee, Candace Y.W., Scott, Christopher, Bailey, Kent R., Schirger, John A., Chen, Horng H., Benike, Sherry L., Cannone, Valentina, Martin, Fernando L., Sangaralingham, S. Jeson, Ichiki, Tomoko, Burnett, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995613/ https://www.ncbi.nlm.nih.gov/pubmed/29226471 http://dx.doi.org/10.1002/cpt.974

Ejemplares similares

Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
por: Martin, Fernando L, et al.
Publicado: (2011)

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011)

M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013)

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014)

Cenderitide-Eluting Film for Potential Cardiac Patch Applications
por: Ng, Xu Wen, et al.
Publicado: (2013)

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation
por: Ma, Xiao, et al.
Publicado: (2023)

A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts
por: Ichiki, Tomoko, et al.
Publicado: (2009)

Natriuretic peptide pathways in heart failure: further therapeutic possibilities
por: Sangaralingham, S Jeson, et al.
Publicado: (2022)

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling
por: Ichiki, Tomoko, et al.
Publicado: (2017)

The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
por: Schirger, John A, et al.
Publicado: (2009)

CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
por: Martin, Fernando L., et al.
Publicado: (2012)

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
por: Boerrigter, Guido, et al.
Publicado: (2011)

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up
por: Buglioni, Alessia, et al.
Publicado: (2015)

Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment
por: Sangaralingham, Jeson, et al.
Publicado: (2009)

C-type natriuretic peptide: the heart’s guardian angel
por: Sangaralingham, S Jeson, et al.
Publicado: (2020)

The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011)

Cardiorenal Effects of Long‐Term Phosphodiesterase V Inhibition in Pre–Heart Failure
por: Hubers, Scott A., et al.
Publicado: (2022)

Renal targeted protein therapeutics in experimental overt heart failure with renal dysfunction
por: Chen, Horng H, et al.
Publicado: (2009)

MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
por: Burnett, John C, et al.
Publicado: (2015)

It's cold, mom! It's cyclic GMP
por: Kuhn, Michaela
Publicado: (2015)

Cyclic GMP and Cilia Motility
por: Wyatt, Todd A.
Publicado: (2015)

Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
por: Petraina, Alexandra, et al.
Publicado: (2021)

Gating by Cyclic Gmp and Voltage in the α Subunit of the Cyclic Gmp–Gated Channel from Rod Photoreceptors
por: Benndorf, Klaus, et al.
Publicado: (1999)

Ultrastructural localization of cyclic GMP and cyclic AMP in rat striatum
Publicado: (1981)

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension
por: Mergia, Evanthia, et al.
Publicado: (2016)

Cyclic GMP and PKG Signaling in Heart Failure
por: Numata, Genri, et al.
Publicado: (2022)

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM
por: Ma, Xiao, et al.
Publicado: (2023)

Mechanism of activation of bacterial cellulose synthase by cyclic-di-GMP
por: Morgan, Jacob L. W., et al.
Publicado: (2014)

A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
por: Lim, Soo Ghim, et al.
Publicado: (2013)

Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets
por: Kleppe, Rune, et al.
Publicado: (2018)

FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons
por: Calamera, Gaia, et al.
Publicado: (2019)

Modulating cGMP in heart failure by novel natriuretic peptides
por: Burnett, John C
Publicado: (2009)

Control of the cyclic GMP phosphodiesterase of frog photoreceptor membranes
Publicado: (1980)

Nitric oxide regulated cyclic di-GMP signaling
por: Boon, Elizabeth M, et al.
Publicado: (2013)

Dexamethasone-dependent modulation of cyclic GMP synthesis in podocytes
por: Lewko, Barbara, et al.
Publicado: (2015)

Cyclic di-GMP signalling and the regulation of bacterial virulence
por: Ryan, Robert P.
Publicado: (2013)

Downregulation of mitochondrial biogenesis by virus infection triggers antiviral responses by cyclic GMP-AMP synthase
por: Sato, Hiroki, et al.
Publicado: (2021)

Adenine protonation enables cyclic-di-GMP binding to cyclic-GAMP sensing riboswitches
por: Keller, Heiko, et al.
Publicado: (2018)

Cyclic GMP protects human macrophages against peroxynitrite-induced apoptosis
por: Shaw, Catherine A, et al.
Publicado: (2009)

A cyclic-di-GMP receptor required for bacterial exopolysaccharide production
por: Lee, Vincent T, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ag31jn4c1t9pjlvud38g291aa5